Literature DB >> 11021528

Soluble CD86 is a costimulatory molecule for human T lymphocytes.

P Jeannin1, G Magistrelli, J P Aubry, G Caron, J F Gauchat, T Renno, N Herbault, L Goetsch, A Blaecke, P Y Dietrich, J Y Bonnefoy, Y Delneste.   

Abstract

CD86 is an important costimulatory molecule for the priming and activation of naive and memory T cells, respectively. Here, we show that soluble CD86 is detected in human serum. Soluble CD86 is produced by resting monocytes and results from an alternatively spliced transcript (CD86deltaTM) characterized by deletion of the transmembrane domain. Recombinant CD86deltaTM binds to CD28 and CTLA-4 and induces the activation of T cells after stimulation with anti-CD3 mAb. CD86deltaTM also induces IFNgamma production by virus-specific CD8+ memory human T cells stimulated with the Flu M1 peptide. The concentrations of soluble CD86 found in human serum are sufficient to induce biological activity. Soluble CD86 molecule, therefore, appears to be a functional costimulatory molecule playing a potentially important role in immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021528     DOI: 10.1016/s1074-7613(00)00030-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  29 in total

1.  Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

Authors:  Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

2.  Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity.

Authors:  Dirk Homann; Wolfgang Dummer; Tom Wolfe; Evelyn Rodrigo; Argyrios N Theofilopoulos; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Impact of toll-like receptor 2 deficiency on immune responses to mycobacterial antigens.

Authors:  Muhammad J Rahman; Olga D Chuquimia; Dagbjort H Petursdottir; Natalia Periolo; Mahavir Singh; Carmen Fernández
Journal:  Infect Immun       Date:  2011-08-15       Impact factor: 3.441

4.  Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.

Authors:  M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 5.  Soluble immune checkpoints in cancer: production, function and biological significance.

Authors:  Daqian Gu; Xiang Ao; Yu Yang; Zhuo Chen; Xiang Xu
Journal:  J Immunother Cancer       Date:  2018-11-27       Impact factor: 13.751

6.  CD28-B7 interaction modulates short- and long-lived plasma cell function.

Authors:  Modesta N Njau; Jin Hyang Kim; Craig P Chappell; Rajesh Ravindran; Leela Thomas; Bali Pulendran; Joshy Jacob
Journal:  J Immunol       Date:  2012-08-20       Impact factor: 5.422

Review 7.  The role of costimulatory molecules in allergic disease and asthma.

Authors:  Vincent Lombardi; Abinav K Singh; Omid Akbari
Journal:  Int Arch Allergy Immunol       Date:  2009-09-29       Impact factor: 2.749

8.  Soluble CD86 protein in serum samples of patients with asthma.

Authors:  H-Z Shi; Z-F Xie; J-M Deng; Y-Q Chen; C-Q Xiao
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

9.  Spontaneous colitis occurrence in transgenic mice with altered B7-mediated costimulation.

Authors:  Gisen Kim; Olga Turovskaya; Matthew Levin; Fergus R Byrne; John S Whoriskey; James G McCabe; Mitchell Kronenberg
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

10.  Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data.

Authors:  Takeshi Azuma; Gefeng Zhu; Haiying Xu; A Cecilia Rietz; Charles G Drake; Eric L Matteson; Lieping Chen
Journal:  PLoS Med       Date:  2009-10-20       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.